Literature DB >> 7436359

Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts.

H W Moser, A B Moser, N Kawamura, J Murphy, K Suzuki, H Schaumburg, Y Kishimoto.   

Abstract

Because postmortem brain and adrenal tissue from patients with adrenoleukodystrophy (ALD) or adrenomyeloneuropathy (AMN) have been shown to contain abnormally large amounts of very long chain fatty acids (C24 through C30), we searched for such an abnormality in cultured skin fibroblasts. Total lipid extracts of cultured fibroblasts were hydrolyzed, their fatty acid composition was determined by gas-liquid chromatography, and the ratio of C26 to C22 fatty acids was calculated. In 29 control cell lines this ratio was 0.064 +/- 0.019. In 5 patients with autopsy-proved ALD the ratio was 0.778 +/- 0.139; in 6 patients with clinical features typical of ALD it was 0.764 +/- 0.092; in 2 patients with autopsy-proved AMN, 0.890 +/- 0.02; and in 2 patients with clinical features typical of AMN, 0.560 +/- 0.079. Abnormal ratios were observed in 4 of 5 ALD heterozygotes. In 3 patients in whom the diagnosis of ALD was suspected, an abnormal ratio (0.860) was observed in 1 and normal ratios (0.06 and 0.074) in the 2 others.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436359     DOI: 10.1002/ana.410070607

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  56 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 3.  Peroxisomal disorders: clinical, biochemical, and molecular aspects.

Authors:  R J Wanders
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 4.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

5.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

6.  A family with adrenoleucodystrophy.

Authors:  R P Singh; S Deshpande; R K Marwaha; K Garg
Journal:  Indian J Pediatr       Date:  1989 Sep-Oct       Impact factor: 1.967

7.  Linkage analysis in X-linked adrenoleukodystrophy and application in post- and prenatal diagnosis.

Authors:  B A van Oost; P M van Zandvoort; W Tünte; H G Brunner; A J Hoogeboom; P D Maaswinkel-Mooy; J Bakkeren; B Hamel; H H Ropers
Journal:  Hum Genet       Date:  1991-02       Impact factor: 4.132

8.  Adrenoleukodystrophy without adrenal insufficiency and its magnetic resonance imaging.

Authors:  H Nishio; S Kodama; T Tsubota; T Takumi; T Takahashi; S Yokoyama; T Matsuo
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

9.  Rational diagnostic strategy for Zellweger syndrome spectrum patients.

Authors:  Cindy Krause; Hendrik Rosewich; Jutta Gärtner
Journal:  Eur J Hum Genet       Date:  2009-01-14       Impact factor: 4.246

10.  Isolated defect of peroxisomal beta-oxidation in a 16-year-old patient.

Authors:  R Santer; A Claviez; H D Oldigs; J Schaub; R B Schutgens; R J Wanders
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.